Ipsen Logo

Ipsen

Biopharmaceutical company developing medicines for oncology, rare diseases, and neuroscience.

IPN | PA

Overview

Corporate Details

ISIN(s):
FR0010259150 (+17 more)
LEI:
549300M6SGDPB4Z94P11
Country:
France
Address:
65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT

Description

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-08 18:30
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total des droi…
French 134.4 KB
2025-12-08 18:30
Ipsen - November 2025 - Monthly information relative to the total number of vot…
English 155.6 KB
2025-10-07 18:30
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 84.4 KB
2025-10-07 18:30
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
English 85.2 KB
2025-09-30 18:30
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
English 81.9 KB
2025-09-30 18:30
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 81.3 KB
2025-09-16 18:30
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 86.5 KB
2025-09-16 18:30
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
English 86.4 KB
2025-09-02 18:00
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 269.9 KB
2025-09-02 18:00
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
English 542.0 KB
2025-07-10 18:30
Ipsen - Juin 2025 - Information mensuelle relative au nombre total des droits d…
French 124.2 KB
2025-07-10 18:30
Ipsen - June 2025 - Monthly information relative to the total number of voting …
English 106.7 KB
2025-07-01 09:00
Gemeinsam fur eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Communi…
German 8.6 KB
2025-06-17 18:00
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
English 271.6 KB
2025-06-17 18:00
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 468.0 KB

Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ipsen

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ipsen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-04 N/A Other Sell 850 91,374.66 EUR
2024-02-27 N/A Other Buy 500 51,916.20 EUR
2023-07-31 N/A Other Buy 50,048 N/A

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.